Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Jun 16;139(2):628–633.e10. doi: 10.1016/j.jaci.2016.04.049

Appendix Table 2.

aGVHD in patients receiving serotherapy compared to those not receiving serotherapy in (a) all patients, and (b) TME(+) patients only.

a) All patients
Serotherapy
Conditioning		 N (%) Serotherapy
N (%)		 No
Serotherapy
N(%)		 RR p
74 (100) 31 (41.9) 43 (58.1)
aGVHD I–IV 27 (36.5) 7 (22.6) 20 (46.5) 0.49 (0.23–1.0) 0.05
aGVHD II–IV 21 (28.4) 4 (12.9) 17 (39.5) 0.33 (0.12–0.88) 0.03
aGVHD III–IV 7 (9.5) 1 (3.2) 6 (14.0) 0.23 (0.029–1.8) 0.23
cGVHD (N=30, 42)^ 6 (8.3) 3 (10.0) 3 (7.1) 1.4 (0.30–6.5) 0.69
b) TME(+) patients only
TME(+) Only N (%) Serotherapy
N (%)		 No
Serotherapy
N(%)		 RR p
35 (47.3) 10 (28.6) 25 (71.4)
aGVHD I–IV 20 (57.1) 3 (30.0) 17 (68.0) 0.44 (0.16–1.2) 0.10
aGVHD II–IV 15 (42.9) 2 (20.0) 13 (52.0) 0.38 (0.11–1.4) 0.15
aGVHD III–IV 5 (14.3) 1 (10.0) 4 (16.0) 0.63 (0.79–4.9) 0.66
cGVHD (N=10, 25)^ 4 (11.4) 1 (10.0) 3 (12.0) 0.83 (0.98–7.1) 0.87
^

cGVHD outcome was restricted to evaluable patients surviving >100 days post-HSCT.